Ionis Pharmaceuticals and Sarepta Therapeutics use ASOs for their RNA therapeutics. Ionis Pharmaceuticals is headquartered in California, USA , and Sarepta Therapeutics in Massachusetts, USA. Ionis has developed over 40 therapeutics (Figure ) and 115 therapeutic/diagnostic patents (Figure ). Sarepta uses antisense technology to target neurological diseases including neuromuscular and neurodegenerative disease with their 11 therapeutics (Figure ). NOXXON Pharma, headquartered in Germany, uses RNA aptamers for their 14 therapeutics (Figure ). Their current pipeline is focused only on oncology, but previously they researched treatments for metabolic, blood, autoimmune, and kidney diseases (Supplemental Table ). Beam Therapeutics, headquartered in Massachusetts, USA , is pioneering the use of base editing with CRISPR/Cas. Beam has 10 therapeutics in development (Figure ). AstraZeneca supports multiple RNA platforms through partnerships with many of the top RNA companies. All but two of the top 15 RNA medicine companies specialize in one type of RNA (Figure ). AstraZeneca supports multiple RNA platforms and CureVac is partnering with CRISPR Therapeutics for their current preclinical CRISPR RNA therapy 136 along with their mRNA therapy. Companies typically specialize in one type of RNA but treat multiple diseases. All but two of the top 15 RNA medicine companies cover multiple diseases. Sarepta specializes in neurological and neuromuscular diseases and NOXXON has supported multiple diseases in the past but is now dedicated exclusively to the treatment of cancer. To investigate the research trends among different types of RNA therapeutics, the collected RNA therapeutics were further grouped by their types and development stages (Figure 13 and 14). The newer types of RNA therapeutics, such as AOCs and CRISPR, often have higher numbers of preclinical trials, indicating a great potential for future drug approval. Whereas, those more established types of RNA therapeutics, such as ASO and siRNA, often have a higher percentage of therapeutics on the market and a higher percentage of active and completed clinical trials, suggesting a shifting of research focus on the early development pipeline.